Literature DB >> 33585495

Thromboembolism in Older Adults.

Peter L Gross1, Noel C Chan1.   

Abstract

Arterial and venous thromboembolism are both more common in older adults. The use of anticoagulants, the mainstay to prevent thromboembolism, requires consideration of the balance between risk and benefit. Such consideration is even more important in the very elderly in whom the risk of anticoagulant-related bleeding and thrombosis are higher. This review will focus on the challenges of implementing and managing anticoagulant therapy in older patients in an era when the options for anticoagulants include not only vitamin K antagonists (VKAs), but also direct-acting oral anticoagulants (DOACs).
Copyright © 2021 Gross and Chan.

Entities:  

Keywords:  COVID-19; atrial fbrillation; direct-acting anticoagulant; falls among older adults; venous thomboembolism; vitamin K antagonist (VKA)

Year:  2021        PMID: 33585495      PMCID: PMC7873530          DOI: 10.3389/fmed.2020.470016

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  85 in total

1.  Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.

Authors:  Ghadeer K Dawwas; Joshua Brown; Eric Dietrich; Haesuk Park
Journal:  Lancet Haematol       Date:  2018-12-14       Impact factor: 18.959

2.  The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Authors:  Stephen E Kimmel; Zhen Chen; Maureen Price; Catherine S Parker; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Robert Gross
Journal:  Arch Intern Med       Date:  2007-02-12

3.  Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study.

Authors:  Carmine Marini; Federica De Santis; Simona Sacco; Tommasina Russo; Luigi Olivieri; Rocco Totaro; Antonio Carolei
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

4.  Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.

Authors:  Ken Okumura; Masaharu Akao; Tetsuro Yoshida; Masahito Kawata; Osamu Okazaki; Shintaro Akashi; Kenichi Eshima; Kimihiko Tanizawa; Masayuki Fukuzawa; Takuya Hayashi; Masahiro Akishita; Gregory Y H Lip; Takeshi Yamashita
Journal:  N Engl J Med       Date:  2020-08-30       Impact factor: 91.245

5.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.

Authors:  Gregory Y H Lip; Amitava Banerjee; Giuseppe Boriani; Chern En Chiang; Ramiz Fargo; Ben Freedman; Deirdre A Lane; Christian T Ruff; Mintu Turakhia; David Werring; Sheena Patel; Lisa Moores
Journal:  Chest       Date:  2018-08-22       Impact factor: 9.410

6.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

7.  Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.

Authors:  Kuan H Ng; Olga Shestakovska; Stuart J Connolly; John W Eikelboom; Alvaro Avezum; Rafael Diaz; Fernando Lanas; Salim Yusuf; Robert G Hart
Journal:  Age Ageing       Date:  2015-11-19       Impact factor: 10.668

8.  Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.

Authors:  Irina Savelieva; Abhay Bajpai; A John Camm
Journal:  Ann Med       Date:  2007       Impact factor: 4.709

9.  Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Jonathan P Piccini; Anne S Hellkamp; Jeffrey B Washam; Richard C Becker; Günter Breithardt; Scott D Berkowitz; Jonathan L Halperin; Graeme J Hankey; Werner Hacke; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Keith A A Fox; Manesh R Patel
Journal:  Circulation       Date:  2015-12-16       Impact factor: 29.690

10.  The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation.

Authors:  Vidya Perera; Beata V Bajorek; Slade Matthews; Sarah N Hilmer
Journal:  Age Ageing       Date:  2009-01-16       Impact factor: 10.668

View more
  1 in total

Review 1.  Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review.

Authors:  Stefano Ballestri; Elisa Romagnoli; Dimitriy Arioli; Valeria Coluccio; Alessandra Marrazzo; Afroditi Athanasiou; Maria Di Girolamo; Cinzia Cappi; Marco Marietta; Mariano Capitelli
Journal:  Adv Ther       Date:  2022-10-16       Impact factor: 4.070

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.